FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097654322> ?p ?o ?g. }

• W3097654322 endingPage "23" @default.
• W3097654322 startingPage "22" @default.
• W3097654322 abstract "Background Most children with Acute Lymphoblastic Leukaemia achieve complete remission and subsequent cure after chemotherapy. But, ALL relapse is the leading cause of treatment failure in paediatric patients, causing long term survival to below. Chemotherapy along with targeted therapies have been explored in relapsed/refractory ALL (R/R ALL) patients. One such targeted therapy is Blinatumomab (Blin), a bi-specific T-cell engagers (BiTEs) antibody, it binds to CD3 receptors on T-cells and CD19 receptors on B-cells thereby re-directing T-cells to exert their cytotoxic effect on malignant as well as non-malignant B-cells. Blin was approved by FDA in March 2018 for the treatment of B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1%. This approval was based on BLAST trial conducted on ≥18-year-old ALL patients. The drug has been studied in children (1-18 years) with five clinical trials exclusively in children of which two have reported their results and three are ongoing. In this systematic review, we evaluated the safety and efficacy of Blin as a monotherapy in paediatric R/R ALL patients. Material/Methods We performed a search on PubMed, Embase, Clinical Trials, Web of Science and Cochrane. We used Mesh Terms ALL and Blinatumomab without any filters. After screening of 1199 articles, 5 clinical trial, 3 retrospective studies and 1 case series were included. These studies included only paediatric patients (&lt;18yrs) evaluating the role of Blin as monotherapy in R/R ALL. We followed the PRISMA guidelines for literature search and selection of studies RESULTS: A total number of patients who received Blin was 320, all were &lt;18 years. The preceding treatment regimens included multi-agent chemotherapy with or without hematopoietic stem cell transplant (HSCT). Five studies included only those patients with more than ≥5% bone marrow blasts. Though many combination monoclonal antibody therapies are available, we included only patients given Blin as monotherapy. Blin therapy was a 4 weeks continuous infusion at a dosage of 5 or 15μg/m2/day followed by 2 weeks of treatment-free interval as one cycle, in the studies, the number of treatment cycles ranged from 1-18. A median follow up in the studies ranged from 6 months to 5 years. Overall, complete response (CR) was found to be 58% (n=184) ranging between 31% to 100%. Following CR with Blin relapse rate was 40% (n=66). The overall median survival ranged from 4.3 to 22 months amongst 5 of the nine studies, while it was reported to be 80% (n=9) survival at the end of 12 months by Elitzur et al and 33.3% (n=3) at the end of two cycles of blin by Schlegel, P et al, the remaining two studies did not mention the duration of overall survival. The cumulative hematologic adverse outcomes of ≥grade 3 amongst the studies reported were neutropenia 22% (n=70), Anemia 27.7%(n=55), thrombocytopenia as reported in four studies was 21.5% (n=30). Fuster J et al. reported a cumulative non-hematologic adverse outcome of 40%(n=6) while other studies reported ≥ grade 3 non-hematologic adverse outcomes with increased liver enzymes, neurologic problems and fever to be most common. Cumulative cytokine release syndrome was reported as 4.7% (n=14) in 6 out of 9 studies. Elitzur et al. reported no non-hematologic adverse effect. We found total cumulative death reported as 17% of cases (n=34). Conclusion Blinatumomab use for R/R ALL paediatric patients treatment showed promising outcomes with more than half of the patients achieving CR. Overall survival has been good with median patient surviving disease-free between 4 to 22 months at large. Though, low mortality indicated long term survival, a high relapse rate points that Blin with combination therapy may show better outcomes. Fifteen ongoing clinical trials are testing Blin currently, three of which are on paediatric R/R ALL group. One trial is testing a combination of Blin and pembrolizumab. The results of these trials will further provide information on its effectiveness in combination therapy. Disclosures Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.:Honoraria, Research Funding, Speakers Bureau." @default.
• W3097654322 created "2020-11-09" @default.
• W3097654322 creator A5004186452 @default.
• W3097654322 creator A5005991606 @default.
• W3097654322 creator A5006668401 @default.
• W3097654322 creator A5008253905 @default.
• W3097654322 creator A5009039474 @default.
• W3097654322 creator A5032489256 @default.
• W3097654322 creator A5037498758 @default.
• W3097654322 creator A5044080455 @default.
• W3097654322 creator A5051078540 @default.
• W3097654322 creator A5058548627 @default.
• W3097654322 creator A5061537738 @default.
• W3097654322 creator A5067538693 @default.
• W3097654322 creator A5085827511 @default.
• W3097654322 date "2020-11-05" @default.
• W3097654322 modified "2023-10-05" @default.
• W3097654322 title "Efficacy and Safety of Blinatumomab for Relapsed or Refractory Pediatric ALL Patients: A Systematic Review" @default.
• W3097654322 doi "https://doi.org/10.1182/blood-2020-137576" @default.
• W3097654322 hasPublicationYear "2020" @default.
• W3097654322 type Work @default.
• W3097654322 sameAs 3097654322 @default.
• W3097654322 citedByCount "1" @default.
• W3097654322 countsByYear W30976543222021 @default.
• W3097654322 crossrefType "journal-article" @default.
• W3097654322 hasAuthorship W3097654322A5004186452 @default.
• W3097654322 hasAuthorship W3097654322A5005991606 @default.
• W3097654322 hasAuthorship W3097654322A5006668401 @default.
• W3097654322 hasAuthorship W3097654322A5008253905 @default.
• W3097654322 hasAuthorship W3097654322A5009039474 @default.
• W3097654322 hasAuthorship W3097654322A5032489256 @default.
• W3097654322 hasAuthorship W3097654322A5037498758 @default.
• W3097654322 hasAuthorship W3097654322A5044080455 @default.
• W3097654322 hasAuthorship W3097654322A5051078540 @default.
• W3097654322 hasAuthorship W3097654322A5058548627 @default.
• W3097654322 hasAuthorship W3097654322A5061537738 @default.
• W3097654322 hasAuthorship W3097654322A5067538693 @default.
• W3097654322 hasAuthorship W3097654322A5085827511 @default.
• W3097654322 hasConcept C121332964 @default.
• W3097654322 hasConcept C126322002 @default.
• W3097654322 hasConcept C142424586 @default.
• W3097654322 hasConcept C143998085 @default.
• W3097654322 hasConcept C187212893 @default.
• W3097654322 hasConcept C2776694085 @default.
• W3097654322 hasConcept C2778020697 @default.
• W3097654322 hasConcept C2778461978 @default.
• W3097654322 hasConcept C2909962599 @default.
• W3097654322 hasConcept C535046627 @default.
• W3097654322 hasConcept C71924100 @default.
• W3097654322 hasConcept C87355193 @default.
• W3097654322 hasConceptScore W3097654322C121332964 @default.
• W3097654322 hasConceptScore W3097654322C126322002 @default.
• W3097654322 hasConceptScore W3097654322C142424586 @default.
• W3097654322 hasConceptScore W3097654322C143998085 @default.
• W3097654322 hasConceptScore W3097654322C187212893 @default.
• W3097654322 hasConceptScore W3097654322C2776694085 @default.
• W3097654322 hasConceptScore W3097654322C2778020697 @default.
• W3097654322 hasConceptScore W3097654322C2778461978 @default.
• W3097654322 hasConceptScore W3097654322C2909962599 @default.
• W3097654322 hasConceptScore W3097654322C535046627 @default.
• W3097654322 hasConceptScore W3097654322C71924100 @default.
• W3097654322 hasConceptScore W3097654322C87355193 @default.
• W3097654322 hasIssue "Supplement 1" @default.
• W3097654322 hasLocation W30976543221 @default.
• W3097654322 hasOpenAccess W3097654322 @default.
• W3097654322 hasPrimaryLocation W30976543221 @default.
• W3097654322 hasRelatedWork W1973891791 @default.
• W3097654322 hasRelatedWork W2351796763 @default.
• W3097654322 hasRelatedWork W2371666691 @default.
• W3097654322 hasRelatedWork W2378355431 @default.
• W3097654322 hasRelatedWork W2403502999 @default.
• W3097654322 hasRelatedWork W2567738959 @default.
• W3097654322 hasRelatedWork W2923882796 @default.
• W3097654322 hasRelatedWork W2954318774 @default.
• W3097654322 hasRelatedWork W2955084311 @default.
• W3097654322 hasRelatedWork W4297834875 @default.
• W3097654322 hasVolume "136" @default.
• W3097654322 isParatext "false" @default.
• W3097654322 isRetracted "false" @default.
• W3097654322 magId "3097654322" @default.
• W3097654322 workType "article" @default.